New International Clinical Guidelines for GLP-1 Medications and Reproductive Health

Global Study Provides Guidance on GLP-1 Use and Female Reproductive Health

The prescribing pipeline for GLP-1 drugs has long lacked a clear protocol for one critical cohort: women of reproductive age — a gap that a new international consensus guideline, published in Obesity Reviews and reported by Technology Networks, now attempts to close. The review represents the first comprehensive set of clinical recommendations for incretin-based medications across the reproductive lifespan, developed by experts from 23 institutions across Europe, North America and the Middle East.

Where the system broke

The rapid uptake of incretin-based medications has outpaced the evidence base for women who are planning pregnancy or become pregnant, according to Dr. Shahrad Taheri, professor and vice dean for adiposity-based chronic diseases at Marshall University Joan C. Edwards School of Medicine. Taheri was the only U.S.-based contributor among the international authors.

That's the bottleneck: a high-volume prescribing line with thin evidence running through one of the highest-stakes patient populations. The authors conclude that nearly half of the clinically important questions around these drugs and reproductive health remain unanswered — a structural gap that any clinic currently prescribing these agents is operating inside without knowing it.

What the review actually delivers

The team systematically analyzed 34 studies — randomized clinical trials, observational data, pharmacovigilance reports, and case reports — to address fertility, pregnancy outcomes, breastfeeding, and postpartum health.

• No increased risk of major congenital anomalies was identified following inadvertent early-pregnancy exposure, though substantial evidence gaps remain, particularly on long-term maternal and child outcomes.
• Incretin-based medications may improve fertility-related outcomes in women with polycystic ovary syndrome (recently renamed polyendocrine metabolic ovarian syndrome, or PMOS) and obesity before pregnancy.
• Current evidence is insufficient to support use during pregnancy or breastfeeding — reinforcing the importance of careful contraceptive counseling and individualized clinical decision-making.

Clinic checklist for now

Until prospective studies and long-term follow-up data land, the practical floor for any clinic prescribing these drugs to women of reproductive age looks like this:

• Document contraception plans at every visit, not just at prescription renewal.
• Treat inadvertent early-pregnancy exposure as a flag for enhanced monitoring, not a reason to terminate.
• Counsel patients explicitly on the evidence gap for breastfeeding — do not extrapolate from adult safety data.
• Flag PCOS/PMOS patients with obesity as a cohort where pre-pregnancy use may support fertility outcomes, with appropriate informed consent.
• Track outcomes locally. Every clinic touching this prescribing line is now part of the evidence base — register, code, and share.